Signature of a silent killer: expression profiling in epithelial ovarian cancer

被引:30
作者
Le Page, C
Provencher, D
Maugard, CM
Ouellet, V
Mes-Mosson, AM
机构
[1] CHU Montreal, Inst Canc Montreal, Ctr Rech, Div Gynecol Oncol,Dept Obstet & Gynecol, Montreal, PQ H2L 4M1, Canada
[2] Univ Montreal, Inst Canc Montreal, Ctr Rech,Ctr Hosp, Dept Med, Montreal, PQ H2L 4M1, Canada
关键词
clinical applications; gene profiling; microarray; ovarian cancer;
D O I
10.1586/14737159.4.2.157
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
With the sequencing of the human genome and the simultaneous development of high-throughput strategies, cancer biologists have entered an exciting new area for gene expression analysis, with the ability to glimpse higher order patterns of genetic and epigenetic alterations in complex diseases. Ovarian cancer biologists are rising to the challenge of applying these new technologies to this silent killer, with the eventual goal of improving the quality of life and long-term survival of patients. This review provides a summary of the disease, a description of available technologies and their application to the ovarian cancer problem, as well as a discussion on the challenges and opportunities related to DNA microarray expression profiling-based research, including downstream clinical applications.
引用
收藏
页码:157 / 167
页数:11
相关论文
共 78 条
[1]   Molecular techniques for studying gene expression in carcinogenesis [J].
Ahmed, FE .
JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART C-ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS, 2002, 20 (02) :77-116
[2]   Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol [J].
Aigner, A ;
Hsieh, SS ;
Malerczyk, C ;
Czubayko, F .
TOXICOLOGY, 2000, 144 (1-3) :221-228
[3]  
[Anonymous], 1973, INT HISTOLOGICAL CLA
[4]   Relapsed ovarian cancer: Challenges and management strategies for a chronic disease [J].
Armstrong, DK .
ONCOLOGIST, 2002, 7 :20-28
[5]  
Bayani J, 2002, CANCER RES, V62, P3466
[6]   Specific keynote: Hereditary ovarian cancer: What we know [J].
Boyd, J .
GYNECOLOGIC ONCOLOGY, 2003, 88 (01) :S8-S10
[7]   Minimum information about a microarray experiment (MIAME) - toward standards for microarray data [J].
Brazma, A ;
Hingamp, P ;
Quackenbush, J ;
Sherlock, G ;
Spellman, P ;
Stoeckert, C ;
Aach, J ;
Ansorge, W ;
Ball, CA ;
Causton, HC ;
Gaasterland, T ;
Glenisson, P ;
Holstege, FCP ;
Kim, IF ;
Markowitz, V ;
Matese, JC ;
Parkinson, H ;
Robinson, A ;
Sarkans, U ;
Schulze-Kremer, S ;
Stewart, J ;
Taylor, R ;
Vilo, J ;
Vingron, M .
NATURE GENETICS, 2001, 29 (04) :365-371
[8]   Identification of prognostic factors in advanced epithelial ovarian carcinoma [J].
Chi, DS ;
Liao, JB ;
Leon, LF ;
Venkatraman, ES ;
Hensley, ML ;
Bhaskaran, D ;
Hoskins, WJ .
GYNECOLOGIC ONCOLOGY, 2001, 82 (03) :532-537
[9]  
Chuaqui R F, 1998, Ann Diagn Pathol, V2, P195, DOI 10.1016/S1092-9134(98)80007-5
[10]   Borderline ovarian tumours: a review of the recent literature [J].
Crispens, MA .
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2003, 15 (01) :39-43